Author Details

Misyurina, E. N.

Issue Section Title File
Vol 8, No 3 (2013) PHARMACOTHERAPY Clinical and biochemical features of some intravenous iron complexes PDF
(Rus)
Vol 17, No 2 (2022) TREATMENT OF HEMATOLOGICAL MALIGNANCIES IN PATIENTS WITH COVID-19: PRO AND CONTRA Chemotherapy of hematological malignancies in patients with COVID-19 PDF
(Rus)
Vol 18, No 4 (2023): Supplement Articles Basic therapeutic approaches to the management of hematology/oncology patients with new coronavirus infection (COVID-19) PDF
(Rus)
Vol 18, No 4 (2023): Supplement Articles Treatment features of adult patients with acute myeloid leukemia during the COVID-19 pandemic PDF
(Rus)
Vol 18, No 4 (2023): Supplement Articles Coronavirus infection after blood stem cell transplantation PDF
(Rus)
Vol 18, No 4 (2023): Supplement Articles Clinical features and treatment strategy for patients with multiple myeloma during the COVID-19 pandemic PDF
(Rus)
Vol 18, No 4 (2023): Supplement Articles Chronic lymphocytic leukemia in combination with COVID-19: clinical features and unfavorable prognosis factors PDF
(Rus)
Vol 18, No 4 (2023): Supplement Articles COVID-19 in patients with acute leukemia: 3 years' experience of pandemic PDF
(Rus)
Vol 18, No 4 (2023): Supplement Articles Treatment experience of coronavirus infection associated with SARS-CoV-2 in patients with acute myeloid leukemia in the older age group PDF
(Rus)
Vol 18, No 4 (2023): Supplement Articles Prognostic model and risk factors for hospital mortality in patients with diffuse large B-cell lymphoma associated with coronavirus infection: a single-center cohort study PDF
(Rus)
Vol 19, No 2 (2024) RARE AND COMPLEX CLINICAL SITUATIONS: DIAGNOSIS AND TREATMENT CHOICE Sinonasal diffuse large B-cell lymphoma: own clinical observation and literature review PDF
(Rus)
Vol 19, No 2 (2024) CURRENT ASPECTS OF COVID-19 TREATMENT APPROACHES WITH SARS-COV-2 VIRUS PERSISTENCE IN ONCOLOGICAL/HEMATOLOGICAL PATIENTS Persistence of a new coronavirus infection in a patient with primary central nervous system large B-cell lymphoma with assessment of the humoral immune response against SARS-CoV-2 PDF
(Rus)
Vol 19, No 3 (2024) NEW DIRECTIONS, DIAGNOSTIC OPPORTUNITIES, AND TREATMENT ADVANCES Treatment efficiency in patients with acute myeloid leukemia from 2019 to 2023 according to the Moscow Cancer Registry PDF
(Rus)
Vol 19, No 3 (2024) TREATMENT OF HEMATOLOGICAL MALIGNANCIES IN PATIENTS WITH COVID-19 COVID-19 in patients with acute lymphoblastic leukemia PDF
(Rus)
Vol 19, No 4 (2024) HEMATOLOGIC MALIGNANCIES: TREATMENT Treatment of elderly patients with acute myeloid leukemia: personal experience PDF
(Rus)
Vol 19, No 4 (2024) NEW DIRECTIONS, DIAGNOSTIC OPPORTUNITIES, AND TREATMENT ADVANCES Nivolumab-containing therapy in patients with newly diagnosed classical Hodgkin lymphoma: own clinical observations and literature review PDF
(Rus)
Vol 19, No 4 (2024) NEW DIRECTIONS, DIAGNOSTIC OPPORTUNITIES, AND TREATMENT ADVANCES Personalized genotype-directed antitumor therapy for newly diagnosed diffuse large B-cell lymphoma: efficacy and toxicity of the R-CHOP-X protocol in a single-center, non-randomized, prospective clinical trial (first results) PDF
(Rus)
Vol 19, No 4 (2024) RARE AND COMPLEX CLINICAL SITUATIONS: DIAGNOSIS AND TREATMENT CHOICE Efficacy of IsaPomDex triplet therapy in double refractory multiple myeloma patients in real clinical practice in Russia PDF
(Rus)
Vol 20, No 3 (2025) HEMATOLOGIC MALIGNANCIES: TREATMENT Molecular phenotype of diffuse large B-cell lymphoma as a basis for a personalized treatment approach of elderly patients PDF
(Rus)
Vol 20, No 3 (2025) HEMATOLOGIC MALIGNANCIES: TREATMENT Experience with acalabrutinib as a component of molecularly adapted antitumor therapy according to the R-CHOP-X protocol in patients with newly diagnosed diffuse large B-cell lymphoma PDF
(Rus)

The website of the journal Oncohematology contains materials intended exclusively for healthcare professionals.

By closing this message, you confirm* that you are a licensed healthcare professional or a student of a medical educational institution.

This one-time confirmation is valid for the next 30 days.